We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$710M
AUM Growth
+$164M
Cap. Flow
+$64.1M
Cap. Flow %
9.04%
Top 10 Hldgs %
36.24%
Holding
113
New
11
Increased
54
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$15.7M
2
INSP icon
Inspire Medical Systems
INSP
+$12.4M
3
AMGN icon
Amgen
AMGN
+$11.3M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.7M
5
QGEN icon
Qiagen
QGEN
+$10M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13.8M
2
IMGN
Immunogen Inc
IMGN
+$11.4M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$8.68M
4
CRL icon
Charles River Laboratories
CRL
+$8.65M
5
ZBH icon
Zimmer Biomet
ZBH
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 98.72%
2 Industrials 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LAB icon
76
Standard BioTools
LAB
$312M
$1.33M 0.19%
603,620
+103,620
+21% +$221K
AMAM
77
DELISTED
Ambrx Biopharma Inc
AMAM
$1.25M 0.18%
87,678
-62,322
-42% -$708K
LQDA icon
78
Liquidia Corp
LQDA
$7.01B
$1.22M 0.17%
101,767
-15,486
-13% -$111K
TKNO icon
79
Alpha Teknova
TKNO
$397M
$1.05M 0.15%
282,236
+48,490
+21% +$120K
SOPH icon
80
SOPHiA GENETICS
SOPH
$635M
$942K 0.13%
+199,997
New +$748K
INZY
81
DELISTED
Inozyme Pharma
INZY
$905K 0.13%
212,432
+36,536
+21% +$130K
ETON icon
82
Eton Pharmaceutcials
ETON
$1.14B
$872K 0.12%
199,168
+34,168
+21% +$137K
BDTX icon
83
Black Diamond Therapeutics
BDTX
$121M
$713K 0.1%
253,717
-266,870
-51% -$626K
TELA icon
84
TELA Bio
TELA
$32.3M
$684K 0.1%
103,375
-63,350
-38% -$366K
TNGX icon
85
Tango Therapeutics
TNGX
$4.31B
$650K 0.09%
65,679
-70,241
-52% -$610K
XFOR icon
86
X4 Pharmaceuticals
XFOR
$425M
$643K 0.09%
25,578
-1,089
-4% -$26.5K
COGT icon
87
Cogent Biosciences
COGT
$6.76B
$569K 0.08%
96,837
-96,800
-50% -$742K
IMUX icon
88
Immunic
IMUX
$217M
$153K 0.02%
10,226
-46,025
-82% -$564K
ASLN
89
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$57.8K 0.01%
13,832
-32,761
-70% -$247K
ACAD icon
90
Acadia Pharmaceuticals
ACAD
$5.07B
– –
-115,777
Closed -$2.41M
ACRS icon
91
Aclaris Therapeutics
ACRS
$860M
– –
-141,758
Closed -$971K
AKRO
92
DELISTED
Akero Therapeutics
AKRO
– –
-116,107
Closed -$5.87M
ANIP icon
93
ANI Pharmaceuticals
ANIP
$1.73B
– –
-111,802
Closed -$6.49M
CRL icon
94
Charles River Laboratories
CRL
$13.6B
– –
-44,160
Closed -$8.65M
ESTA icon
95
Establishment Labs
ESTA
$2.25B
– –
-60,530
Closed -$2.97M
EVH icon
96
Evolent Health
EVH
$471M
– –
-103,320
Closed -$2.81M
EW icon
97
Edwards Lifesciences
EW
$53.6B
– –
-40,000
Closed -$2.77M
HCA icon
98
HCA Healthcare
HCA
$89.8B
– –
-56,160
Closed -$13.8M
LXRX icon
99
Lexicon Pharmaceuticals
LXRX
$1.05B
– –
-1,136,413
Closed -$1.24M
MIRM icon
100
Mirum Pharmaceuticals
MIRM
$6.04B
– –
-65,050
Closed -$2.06M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Parkman Healthcare Partners held 113 positions worth $710M, up 30% from $546M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners deployed $64.1M of net new capital in Q4 2023, opening 11 new positions and adding to 54 existing holdings. Its largest new stake was Abbott: 156,727 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Becton Dickinson, an estimated $7.52M trimmed.

  • Parkman Healthcare Partners's largest Q4 2023 buy was Abbott: 156,727 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Inspire Medical Systems in Q4 2023, an estimated $12.4M increase.
  • Parkman Healthcare Partners's biggest Q4 2023 reduction was Becton Dickinson, cutting an estimated $7.52M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q4 2023, selling an estimated $13.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $710M portfolio in Q4 2023.
  • Parkman Healthcare Partners opened 11 new positions and closed 24 in Q4 2023.
  • Parkman Healthcare Partners's portfolio value rose 30% quarter-over-quarter to $710M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.